Epidermodysplasia verruciformis



Epidermodysplasia verruciformis


Slawomir Majewski and Stefania Jablonska


Evidence Levels:  A Double-blind study  B Clinical trial ≥ 20 subjects  C Clinical trial < 20 subjects  D Series ≥ 5 subjects  E Anecdotal case reports


image


Epidermodysplasia verruciformis (EV) is a rare genetic disease characterized by an impaired immune response to human papillomavirus (HPV) and HPV-associated cutaneous oncogenesis. Chronic infection occurs with potentially oncogenic HPV types 5 and 8 as well as non-oncogenic types. Flat warts and pityriasis versicolor-like lesions begin to appear in early childhood and become widespread. In the fourth and fifth decades many patients begin to develop multiple cutaneous malignancies. It has been established that EV is mostly associated with mutations of genes EVER1 and EVER2, coding transmembrane proteins located in the endoplasmic reticulum and involved in zinc transportation.


A new and important problem is the occurrence of the EV phenotype in immunosuppressed individuals, especially in association with HIV, which has been called ‘acquired epidermodysplasia verruciformis.’ This differs in response to therapies and outcome. Two varieties of acquired EV are described: a generalized verrucosis associated with large common warts mainly of HPV-3 type (sometimes referred to as benign EV), and a variety associated with diverse HPVs of types not usually related to EV.


The high risk of malignant transformation in genetic EV seems to be reduced in the acquired variety.



Management strategy


No compound acts directly on HPV, and no therapy produces a complete and sustained clearing of both benign wart-like and keratotic lesions associated with oncogenic EV HPVs. A most important aspect of the management of EV is protection from ultraviolet radiation, which is a cancer cofactor. Light-avoiding behavior and topical sunblock creams (sun protection factor >50) are indicated. Other cancer cofactors (radiotherapy, immunosuppressants) must be avoided. Premalignant and troublesome benign lesions can be treated by a variety of destructive techniques: surgical (cryotherapy, shave excision, curettage, laser, full excision) or chemical (trichloroacetic acid, 5% 5-fluorouracil).


For more widespread lesions, with signs of premalignancy or malignancy, agents that modify keratinization are indicated, such as oral or topical retinoids, vitamin D3 analogs, interferons, and imiquimod. Photodynamic therapy (PDT) can be useful for early malignancy. Larger malignancies can necessitate skin autografts.



Specific investigations











Related posts:

Cat scratch disease Hemangiomas Tinea capitis Necrolytic migratory erythema Nevoid basal cell carcinoma syndrome Rocky Mountain spotted fever and other rickettsial infections

Stay updated, free articles. Join our Telegram channel
Tags:
Aug 7, 2016 | Posted by in Dermatology | Comments Off on Epidermodysplasia verruciformis

Full access? Get Clinical Tree
Get Clinical Tree app for offline access